Repligen Corporation (RGEN) Stock Price & How to Invest

Repligen Corporation makes consumable products and equipment used to manufacture biologic drugs, including monoclonal antibodies, gene therapies and vaccines. Its portfolio spans four franchises: filtration (KrosFlo and XCell ATF systems), chromatography resins and columns, proteins (notably Protein A ligands used to purify antibodies), and process analytics. Because roughly 80% of its offerings face limited direct competition and its consumables are embedded in customers' validated manufacturing processes, Repligen sells into a durable, recurring bioprocessing demand base rather than one-off equipment cycles.

The investment picture is one of recovery from the post-pandemic bioprocessing destocking slump. In Q1 2026 revenue rose 15% as reported and 11% organic, with China sales doubling and analytics surging, prompting management to raise adjusted EPS guidance. Trailing-twelve-month revenue sits near $708 million and full-year 2026 guidance calls for roughly $810 million to $840 million. The debate for investors centers on valuation: at a market cap around $9.4 billion the stock trades near 8 times sales, so the shares price in a sustained return to double-digit growth.

Repligen trades at a rich valuation (around 8 times sales), so any stumble in organic growth or guidance can trigger sharp multiple compression. The business is cyclical and sensitive to biopharma capital spending, funding conditions for smaller biotech customers, and inventory destocking, all of which hurt results in 2023 to 2024. Concentration among large pharma and CDMO customers, exposure to China and global tariff or trade policy, and integration risk from ongoing acquisitions add uncertainty. Competition from far larger rivals like Danaher's Cytiva and Sartorius could pressure pricing in overlapping product lines. Finally, as an equipment and consumables supplier, revenue can be lumpy quarter to quarter.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Repligen Corporation's investor relations page or your broker.

• Revenue (TTM): ~$708M
• FY2026 revenue guidance: ~$810M to $840M
• Q1 2026 revenue growth: ~15% reported (11% organic)
• FY2026 adjusted EPS guidance: ~$1.97 to $2.05
• Market cap: ~$9.4B
• Price/sales: ~8x

Repligen carries a premium valuation typical of high-quality life-science tools names, with a price-to-sales ratio near 8 despite mid-teens headline revenue growth. Management raised its 2026 profit outlook while roughly holding revenue guidance, reflecting a recovery that is more visible in margins than in top-line acceleration so far. The shares are widely viewed as fully priced on sales even if cash flow looks more reasonable.

There are three common ways to get RGEN exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so RGEN sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where RGEN fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Repligen is a high-quality, high-multiple bioprocessing supplier whose story hinges on whether reaccelerating organic growth can justify a valuation of roughly 8 times sales.

Whether RGEN is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is RGEN a buy?, and where the stock could go from here in the RGEN stock forecast.

For income investors, whether RGEN pays a dividend and how the payout looks is covered in does RGEN pay a dividend?